Accounts Receivable, after Allowance for Credit Loss, Current of EUPRAXIA PHARMACEUTICALS INC. from 31 Dec 2023 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
EUPRAXIA PHARMACEUTICALS INC. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Dec 2023 to 31 Dec 2025.
  • EUPRAXIA PHARMACEUTICALS INC. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Dec 2025 was $716,095, a 177% increase year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

EUPRAXIA PHARMACEUTICALS INC. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $716,095 +$458,021 +177% 31 Dec 2025 40-F 13 Mar 2026 2025 FY
Q4 2024 $258,074 +$104,325 +68% 31 Dec 2024 40-F 13 Mar 2026 2025 FY
Q4 2023 $153,749 31 Dec 2023 40-F 20 Mar 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.